As insulin sensitizers, they may modify CV risk factors and reduce CV mortality in T2DM and insulin resistance subjects.[16] The ACE inhibitors therapy reduces both microvascular and macrovascular complications in diabetes and appears to improve insulin sensitivity and glucose metabolism.[17] This review focuses on the potential roles of rosiglitazone, a member of TZD class of antidiabetic agents, and ramipril, an ACE inhibitor, in preventing the preclinical macrovasculopathy in diabetes and IGT population. This evidence concerns the gene ACE and type 2 diabetes mellitus.